MISRII EVs
EVs bioengineered with human MISRII receptor
Reference X139
MISRII EVs are bioengineered EVs, harbouring human MISRII receptor (Muellerian inhibiting substance type II receptor) at their surface using Ciloa’s pilot peptide technology.
MISRII EVs are produced in human embryonic kidney (HEK) 293T cell line and purified according to in-EV purification process, combining Tangential Flow Filtration and chromatography. Pure MISRII EVs are subjected to standardised quality controls showing the total protein content, the number of particles, the EV size distribution, the presence of internal EV markers and the absence of cell protein contaminants. A direct ELISA on pure MISRII EVs reveals the CD81 surface marker. Cellular expression of MISRII and its sorting with EVs, are given.
Strengths of MISRII EVs
o Purity: in-EV standardised purification process combining Tangential Flow Filtration (TFF) and chromatography allows to obtain highly purified EVs.
o Quality: MISRII EVs have been characterised using in-EV standardised quality controls.
o Storage: MISRII EVs are in a simple buffer and are stable at +4°C for several months.
o Native: MISRII is expressed at the EV surface in its mature conformation.
o Many applications: MISRII EVs can be used to study molecular interactions with ligands, specific antibodies or small molecules.
| Total protein quantity of pure EVs | 50 µg |
| Particle number (Nano-flow cytometry) | ≥ 8 x109 particles |
| Particle size (Nano-flow cytometry) | Median size of 60-70 nm |
| Source | HEK293T cells |
| Buffer | PBS 1X – BSA 10 µg/mL |
| Storage | Store sterile at +4°C up to 6 months |
Schematic representation of MISRII EVs
Created using biorender.com
Western Blot analysis shows that MISRII on EVs acquired post-translational modifications such as N-glycosylations.